Rifaximin for the Secondary Prevention of Recurrent Pouchitis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rifaximin for the Secondary Prevention of Recurrent Pouchitis — Stella

Home/Pouchitis/

View on ClinicalTrials.gov

Recruiting

Back to Pouchitis trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

United States

NYU IBD Center, New York, New York

University of North Carolina, Chapel Hill, North Carolina

Key details

Phase

Post-approval study

Sponsor

University of North Carolina, Chapel Hill

Collaborators

Bausch Health Americas, Inc.

Enrollment target

~16 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years – 74 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.